Is PCA3 score useful in preoperative staging of a single microfocus of prostate cancer diagnosed at saturation biopsy?

Urologia Internationalis

Volumn 89, Issue 2, 2012, Pages 143-147

  Pepe, Pietro ^a   Fraggetta, Filippo ^a   Galia, Antonio ^a   Aragona, Francesco ^a  

^a CANNIZZARO HOSPITAL   (Italy)

Author keywords

Insignificant prostate cancer; Microfocus of prostate cancer; PCA3; Prostate cancer staging; Saturation prostate biopsy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; ASSAY; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3 SCORE; RADICAL RETROPUBIC PROSTATECTOMY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

AGED; ANTIGENS, NEOPLASM; BIOPSY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE CARE; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 84866243452     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000340055     Document Type: Article

References (28)

1. Schroder FH, Hugosson J, Roobol MJ, et al: Screening of prostate cancer mortality in randomized European study. N Engl Med 2009; 360: 1320-1328.
2. Makarov DV, Trock BJ, Humphreys EB, et al: Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69: 1095- 1101.
3. Kattan MW, Cuzick J, Fisher G, et al: Nomogram incorporating PSA level to predict cancer- specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer 2008; 112: 69-74.
4. Algaba F, Arce Y, Oliver A, et al: Prognostic parameters other than Gleason score for the daily evaluation of prostate cancer in needle biopsy. Eur Urol 2005; 48: 566-571.
5. Freedland SJ, Terris MK, Csathy GS, et al: Preoperative model for predicting PSA recurrence after radical prostatectomy using percent of biopsy with cancer, biopsy Gleason grade and serum PSA. J Urol 2004; 171: 2215-2220.
6. Pepe P, Fraggetta F, Galia A, et al: Is quantitative histology useful to predict nonorganconfined prostate cancer when saturation biopsy is performed? Urology 2008; 72: 1198- 1202.
7. Lee AK, Doytchinova T, Chen M, et al: Can the core length involved with prostate cancer identify clinically insignificant disease in low risk patients diagnosed on the basis of a single positive core? Urol Oncol 2003; 21: 123-127.
8. Epstein J, Walsh P, Carmichael M: Pathological and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-374.
9. Postma R, de Vries SH, Roobol MJ, et al: Incidence and follow up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years. Cancer 2005; 103: 798-816.
10. Pepe P, Aragona F: Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. Urology 2007; 70: 1131-1135.
11. Thong AE, Shikanov S, Katz MH, et al: A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy - can we predict adverse pathological outcomes? J Urol 2008; 180: 2436-2440.
12. Allan RW, Sanderson H, Hepstein JI: Correlation of minute (0.5 mm or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: Role of prostate specific antigen density. J Urol 2003; 170: 370-372.
13. Epstein JI, Sanderson H, Carter HB, et al: The utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology 2005; 66: 356-360.
14. Harnden P, Naylor B, Shelly MD, et al: The clinical management of patients with a small volume of prostatic cancer on biopsy: What are the risks of progression? A systematic review and meta-analysis. Cancer 2008; 112: 971-981.
15. Ploussard G, Durand X, Xylinas E, et al: Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 2011; 59: 422-429.
16. Pepe P, Aragona F: Incidence of insignificant prostate cancer using free/total PSA: Results of a case-finding protocol on 14,453 patients. Prostate Cancer Prostatic Dis 2010; 13: 316- 319.
17. Groskopf J, Aubin SM, Deras IL, et al: APTIMA molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52: 1089-1095.
18. Bostwick DG, Grignon DJ, Hammond ME, et al: Prognostic factors in prostate cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 995-1000.
19. Mottet N, Irani J: Active surveillance in prostate cancer: The French protocol. Prog Urol 2008; 18: 212-216.
20. Hessels D, van Gils MP, van Hooij O, et al: Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010; 70: 10-16.
21. Haider MA, van der Kwast TH, Tanguay E, et al: Combined T2-weighted and diffusionweighted MRI for localization of prostate cancer. AJR 2007; 189: 323-328.
22. Pepe P, Candiano G, Fraggetta F, et al: Is a single focus of low grade prostate cancer, diagnosed on saturation biopsy, predictive of clinically insignificant cancer? Urol Int 2010; 84: 440-444.
23. Boccon-Gibod LM, Barry de Longchamps N, Toublanc M, et al: Prostate saturation biopsy in the reevaluation of microfocal prostate cancer. J Urol 2006; 176: 961-964.
24. Vlaeminck-Guillem V, Devonec M, Colombel M, et al: Urinary PCA3 score predicts prostate cancer multifocality. J Urol 2011; 185: 1234-1239.
25. Aubin SM, Reid J, Sarno MJ, et al: PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of dutasteride REDUCE trial. J Urol 2010; 184: 1947-1952.
26. Haese A, de la Taille A, van Poppel H, et al: Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54: 1081-1088.
27. Whitman EJ, Groskopf J, Ali A, et al: PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008; 180: 1975-1978.
28. Auprich M, Chun FK, Ward JF, et al: Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 2011; 59: 96-105.